Abstract WFH_final_re-submission.pdf (68.7 kB)
HemAcure: Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe haemophilia A
conference contribution
posted on 2018-10-30, 11:14 authored by Cristina Olgasi, Simone Merlin, Patrick Bittorf, Delfina Mazzuca, Alexandra StolzingAlexandra Stolzing, Philip Toleikidis, Martin Zierau, Antonia Follenzi, Joris Braspenning, Thorsten BergmannHemAcure: Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe haemophilia A
History
School
- Mechanical, Electrical and Manufacturing Engineering
Published in
HAEMOPHILIAVolume
24Pages
66 - 66Citation
OLGASI, C. ... et al., 2018. HemAcure: Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe haemophilia A [W‐P‐052 (548)] . Haemophilia, 24(Suppl. 5) pp. 66.Publisher
WileyVersion
- AM (Accepted Manuscript)
Publisher statement
This work is made available according to the conditions of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) licence. Full details of this licence are available at: https://creativecommons.org/licenses/by-nc-nd/4.0/Publication date
2018Notes
This is an abstract of a paper presented at WFH 2018 World Congress, Glasgow, Scotland May 20-24, 2018. This is the peer reviewed version of the following article: OLGASI, C. ... et al., 2018. HemAcure: Application of combined gene and cell therapy within an implantable therapeutic device for the treatment of severe haemophilia A [W‐P‐052 (548)] . Haemophilia, 24(Suppl. 5) pp. 66, which has been published in final form at https://doi.org/10.1111/hae.13478. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.ISSN
1351-8216eISSN
1365-2516Publisher version
Language
- en